Vivani Medical (VANI) to Release Earnings on Monday

Vivani Medical (NASDAQ:VANI) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Vivani Medical to post earnings of ($0.10) per share for the quarter.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, analysts expect Vivani Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vivani Medical Trading Up 1.5 %

Shares of NASDAQ VANI opened at $1.04 on Friday. The firm has a market cap of $61.32 million, a P/E ratio of -2.30 and a beta of 2.81. The business’s 50 day moving average is $1.05 and its 200-day moving average is $1.17. Vivani Medical has a 1-year low of $0.91 and a 1-year high of $2.09.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Vivani Medical in a report on Wednesday, April 16th.

Insiders Place Their Bets

In related news, Director Gregg Williams purchased 44,400 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $43,956.00. Following the completion of the purchase, the director now owns 4,799,200 shares in the company, valued at approximately $4,751,208. This represents a 0.93 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired a total of 108,922 shares of company stock worth $108,769 in the last quarter. Corporate insiders own 44.30% of the company’s stock.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.